A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Clinical trial NCT06277024 · RECRUITING
Trial details
- NCT number
- NCT06277024
- Sponsor
- Fujian Medical University
- Status
- RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-01
- Primary completion
- 2024-12-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.